PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1720017
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1720017
Prothrombin Complex Concentrate Market size was valued at USD 2,590 Million in 2024, expanding at a CAGR of 9.80% from 2025 to 2032.
Prothrombin Complex Concentrate (PCC), also known as factor X complex, is a medication composed of the blood clotting factors X, IX, and X. Some versions also include factor Vll. It is used to treat and prevent bleeding in hemophilia B patients when pure factor IX is not available. It may also be used in those who do not have enough of these components due to other factors, such as warfarin treatment. It is administered into the body via a needle or syringe into a vein. Common side effects include allergic reactions, regurgitation, headaches, and sleepiness. It can also have serious side effects, such as blood clots, which can lead to a heart attack, stroke, or pulmonary embolism.
Prothrombin Complex Concentrate Market- Market Dynamics
Advancements in Medical Technology and Research
Medical technological advancements are paving the way for better formulations and delivery methods of prothrombin complex concentrates. Innovations in processing techniques, laboratory technology, and patient treatment systems have resulted in improved PCC product efficacy and safety. These advancements benefit the Prothrombin Complex Concentrate PCC Market Industry by broadening the scope of PCC applications and improving patient outcomes. As research advances to develop more effective treatments, healthcare providers are more likely to use prothrombin complex concentrates in their clinical practices, propelling market growth even further. For instance, in March 2019, Grifols S.A. entered into a strategic agreement to control 26.2% of Shanghai RAAS in exchange for a non-minority stake in Grifols Diagnostic Solutions. This collaboration will help Grifols expand its plasma-derived products in the Chinese market.
Prothrombin Complex Concentrate Market- Key Insights
According to our research analyst, the global market is expected to grow at a compound annual growth rate (CAGR) of roughly 9.80% between 2025 and 2032.
The 4-factor PCC category is predicted to be the biggest during the projection period, according to Product Type segmentation.
Throughout the forecast period, the hospitals and ambulatory surgery segment is anticipated to dominate the market, based on End Use segmentation.
Based on region, North America was the leading revenue generator in 2024
The Global Prothrombin Complex Concentrate Market is segmented based on Product Type, Application, End Use, and Region.
Product Type divides the market into two groups: 3-factor PCC and 4-factor PCC. The 4-factor segment accounted for the majority of the PCC market share in 2023. The primary factors contributing to the segment's dominant share are increased penetration of 4-factor PCC brands such as Kcentra and Beriplex in emerging countries and clinically proven efficacy for urgent warfarin reversal. Aside from that, active government support to reduce warfarin-related adverse events is likely to benefit the segment.
According to end uses, the market is separated into three categories: Hospitals, Ambulatory surgical centers, and other end users. The hospitals and ambulatory surgery segment are expected to dominate the market over the forecast period due to rising demand for prothrombin complex concentrate, positive government recommendations, and increased hospital purchases of plasma products as a result of the COVID-19 pandemic. The specialty clinics segment is expected to grow due to the rising number of surgeons and privately owned clinics.
Prothrombin Complex Concentrate Market- Geographical Insights
This market is geographically dispersed throughout Europe, the Middle East, Africa, Latin America, Asia Pacific, and North America. The nations that bring commerce further divide these regions. In 2023, North America emerged as the largest market for the global Prothrombin Complex Concentrates Market. The presence of significant players in the area is expected to fuel market growth in the region. Furthermore, the introduction of new health insurance policies to cover uncommon blood illnesses, as well as the expansion of plasma collection centers in North America, adds to the market's growth.
The Asia-Pacific market is expected to grow at the fastest CAGR between 2025 and 2032. The market for Prothrombin Complex concentrates in the Asia-Pacific region and is expanding as healthcare becomes more accessible. The rapidly growing demand for minimally invasive medical procedures, fueled by the growing middle-class population in China and India, also fuels the market's expansion.
The market for prothrombin complex concentrate is competitive, with industry leaders such as CSL Behring, Octapharma, Emergent BioSolutions, and Grifols. These players are engaged in the production of high-quality products to meet the rising demand for effective therapies in the management of bleeding disorders, especially in patients receiving anticoagulation therapy. The market is fueled by growing awareness of hemophilia and other coagulation disorders, which drives innovation and improvement in product efficacy and safety. In addition, strategic partnerships, mergers, and expansions are typical practices undertaken by these organisations to enhance their market position and expand their global presence, to cater to the changing needs of healthcare providers and patients. For instance, in July 2021, Takeda announced plans to acquire Maverick Therapeutics, a biotech company, to expand its oncology and hematology portfolio.
In October 2021, Sanquin and Octapharma formed a long-term collaboration to develop and manufacture a prothrombin complex aimed specifically at treating bleeding disorders.